Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2021 | Latest updates on treating plasma cell dyscrasias

Meral Beksac, MD, Ankara University, Ankara, Turkey, shares the latest updates on the treatment of plasma cell dyscrasias, as presented at EBMT 2021. Dr Beksac outlines the discovery and utilization of novel biomarkers, such as translocation of (11;14), as well as new data from the Phase III ANDROMEDA trial (NCT03201965) investigating daratumumab for the treatment of amyloidosis, bispecific antibody therapies, and the latest updates in chimeric antigen receptor T-cell (CAR-T) therapy. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Disclosures

Dr Meral Beksac, MD, has participated in advisory boards or speakers bureaus with Amgen, BMS, Celgene, Janssen, Oncopeptides, Sanofi and Takeda.